11
VES-13 score has been
shown to be associated
with mortality,
chemotherapy toxicity,
and functional decline.
Administered or PRO
(but errors are common
with PRO administration);
5-10 min
VES-13 can also be used as
a screening tool to identify
older patients who need more
comprehensive GA
Study Population
Administration
characteristics Considerations
Low SPPB score
associated with increased
mortality in older
women with g ynecologic
malignancies.
TUG and gait speed
have been shown to be
associated with early
mortality (6 months)
in older patients
with cancer receiving
chemotherapy.
SPPB and gait speed
associated with
functional decline in
patients with non-
metastatic breast cancer
receiving chemotherapy.
All administered; 1-5 min
depending on test
